The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?

Cancer cell ·Vol. 2 ·No. 5 ·2002-11-00 ·Pages 349-50

Sellers WR, Loda M

Abstract

The recent finding of overexpression of the polycomb group transcriptional repressor EZH2 in prostate cancer raises the possibility that transcriptional regulation at the chromatin level may play a role in the development of the metastatic phenotype and suggests new avenues of exploration with respect to patient stratification and therapeutics.

MeSH Terms

Biomarkers, Tumor DNA-Binding Proteins Enhancer of Zeste Homolog 2 Protein Gene Expression Profiling Gene Expression Regulation Humans Male Oligonucleotide Array Sequence Analysis Polycomb Repressive Complex 2 Prostatic Neoplasms/genetics,secondary,surgery Proteins/analysis,metabolism RNA, Messenger/genetics,metabolism Repressor Proteins/genetics,physiology Transcription Factors Transcription, Genetic Treatment Outcome

Chemicals

Biomarkers, Tumor DNA-Binding Proteins Proteins RNA, Messenger Repressor Proteins Transcription Factors EZH2 protein, human Enhancer of Zeste Homolog 2 Protein Polycomb Repressive Complex 2

Authors & Affiliations

2 authors, click to expand affiliations / ORCID

Sellers William R

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. [email protected]

Loda Massimo

Article Info

Journal

Cancer cell

Abbr.

Cancer Cell

ISSN

1535-6108

DOI

10.1016/s1535-6108(02)00187-3

[email protected]

Published

2002-11-00

Pages

349-50

Language

English

Region

United States

NLM ID

101130617

Subset

External Links

PubMed source DOI: 10.1016/s1535-6108(02)00187-3 View journal details

Analysis Services

The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?

Contact

WeChat Official Account